SCHEMBL858260

SCHEMBL858260

CCOC(=O)C(C)C(=O)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
LMNA P02545 2/20 0.42
HSD17B10 Q99714 1/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 2/20 0.40
ALOX15 P16050 1/20 0.40
MGAM O43451 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
SOAT1 P35610 1/20 0.40
TRPA1 O75762 1/20 0.37
CA12 O43570 3/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA7 P43166 3/20 0.34
CA9 Q16790 3/20 0.34
CA14 Q9ULX7 3/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
PIN1 Q13526 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143571 0.90 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10HPGDGAA
SCHEMBL141446 0.84 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10HPGDGAA
SCHEMBL11240243 0.83 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10HPGDGAA
SCHEMBL28186389 0.81 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10HPGDGAA
Ammonia Solution, Strong SCHEMBL28791130 0.81 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10HPGDGAA
Ethane SCHEMBL9181718 0.81 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10HPGDGAA
SCHEMBL8800602 0.81 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10HPGDGAA
SCHEMBL29568445 0.81 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10HPGDGAA
SCHEMBL15437945 0.81 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10HPGDGAA
SCHEMBL6247104 0.81 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119100988-A Preparation method of hydroxypyrazole derivative under action of alkali 山东京博农化科技股份有限公司 2024-12-10 CN disclosed
US-20230124115-A1 DELTA LACTONES THROUGH ENGINEERED POLYKETIDE SYNTHASES UNITED STATES DEPARTMENT OF ENERGY 2023-04-20 US disclosed
US-20230124115-A1 DELTA LACTONES THROUGH ENGINEERED POLYKETIDE SYNTHASES UNITED STATES DEPARTMENT OF ENERGY 2023-04-20 US disclosed
WO-2021226415-A1 DELTA LACTONES THROUGH ENGINEERED POLYKETIDE SYNTHASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-11-11 WO disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 US disclosed
EP-3041474-B1 ANTIPROLIFERATIVE COMPOUNDS GENENTECH INC (US) 2020-03-18 EP disclosed
US-9815842-B2 Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors NOVARTIS AG (CH) 2017-11-14 US disclosed
US-20170121335-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS NOVARTIS AG (CH) 2017-05-04 US disclosed
US-9505767-B2 Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors GENENTECH, INC. (US) 2016-11-29 US disclosed
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
CN-103459384-A Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS INC 2013-12-18 CN disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
CN-102459249-A Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases EXELIXIS INC 2012-05-16 CN disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3395/4885LMNA 2593/4885HSD17B10 1254/4885
US-11001590-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 ALDH1A1 1228/4885LMNA 2619/4885HSD17B10 4479/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3533/4885LMNA 2817/4885HSD17B10 711/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3049/4885LMNA 2157/4885HSD17B10 1066/4885
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 ALDH1A1 1241/4885LMNA 3036/4885HSD17B10 4590/4885
US-20170121335-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS MMEL1, MALT1, FBP1 ALDH1A1 2655/4885LMNA 4214/4885HSD17B10 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.